Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13613683 | 0.89 | PARP1 (0.52) | PARP1PREPMEN1KMT2A | |
| SCHEMBL13613689 | 0.86 | PREP (0.38) | PARP1PREP | |
| SCHEMBL13628796 | 0.84 | GRM2 (0.46) | ALDH1A1GRM2 | |
| SCHEMBL12581794 | 0.83 | ALDH1A1 (0.43) | ALDH1A1POLBRAB9APARP1PREP | |
| SCHEMBL19242396 | 0.83 | CHRM1 (0.47) | — | |
| SCHEMBL8271979 | 0.80 | ALDH1A1 (0.42) | ALDH1A1POLBRAB9AGRM2 | |
| SCHEMBL13952126 | 0.78 | ALDH1A1 (0.43) | ALDH1A1POLBRAB9APARP1PREP | |
| SCHEMBL13952244 | 0.75 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL2022098 | 0.75 | PARP1 (0.49) | ALDH1A1POLBRAB9APARP1PREP | |
| SCHEMBL12441982 | 0.75 | POLB (0.40) | ALDH1A1POLBRAB9APARP1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | ALDH1A1 1582/4885POLB 3451/4885RAB9A 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.